MedTrace Logo

GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03)

NCT04706273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321

Last updated 2024-09-20

Study results available
· View outcomes & findings →

Summary

This study will confirm device efficacy and safety in the clinical setting after the launch of the GORE® VIABAHN® Endoprosthesis for the treatment of symptomatic peripheral arterial disease in the superficial femoral arteries.

Conditions

  • Peripheral Arterial Disease

Interventions

DEVICE

GORE® VIABAHN® Endoprosthesis

Participants receiving the GORE® VIABAHN® Endoprosthesis

Sponsors & Collaborators

  • W.L.Gore & Associates

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-25
Primary Completion
2019-07-11
Completion
2022-12-14
FDA Device
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706273 on ClinicalTrials.gov